Why the study?
While anticoagulation reduces thromboembolic risk in clinical AF, its benefit-risk profile for secondary stroke prevention in device-detected atrial fibrillation remains uncertain.
Does anticoagulation reduce any stroke recurrence in patients with device-detected atrial fibrillation post-stroke or TIA?
Population
599 patients with DDAF post stroke or TIA across 2 RCTs
Comparison
Anticoagulation vs no-anticoagulation
Design
Systematic review and meta-analysis of RCTs
Key result
Anticoagulation significantly reduced any stroke recurrence (RR 0.47; 95% CI 0.23-0.94; p=0.034) but increased major bleeding risk (RR 2.30) in patients with DDAF post-stroke or TIA.
Authors
Loading...
Requires individualized risk stratification for anticoagulation in device-detected AF post-stroke/TIA; challenges weak prior consensus against benefit.
Meta-Analysis (n=599)
Does anticoagulation reduce any stroke recurrence in patients with device-detected atrial fibrillation post-stroke or TIA?
Effect estimate: RR 0.47 (95% CI 0.23-0.94)
p-value: p=0.034
Anticoagulation in patients with device-detected AF post-stroke/TIA reduces stroke recurrence but increases major bleeding risk, highlighting the need for individualized risk stratification.
Palaiodimou et al. (2025) conducted a meta-analysis in Device-detected atrial fibrillation post stroke or transient ischemic attack (n=599). Anticoagulation vs. No-anticoagulation was evaluated on Any stroke recurrence (RR 0.47, 95% CI 0.23-0.94, p=0.034). Anticoagulation significantly reduced any stroke recurrence (RR 0.47; 95% CI 0.23-0.94; p=0.034) but increased major bleeding risk (RR 2.30) in patients with DDAF post-stroke or TIA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: